The Patent Finder

Kronos Bio, Inc.

12 patents currently held · Updated Nov 21, 2026
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Dec 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 1, 2027
    The maintenance fee for 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma (US 9,120,811) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
  • 2 fees due Jun 15 to 19, 2027 · next Jun 15

Which patents, and when each one lapses · Pro

Recent changes

  • 3 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,450,3216-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
In force
 · USPTO record
In forceUSPTO record
US 8,455,493Imidazopyrazine Syk Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,962,835Imidazopyrazine Syk Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,120,8116-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma
In force
 · USPTO record
In forceUSPTO record
US 9,212,1916-(2,3-Dihydro-1H-PYRIDO-[2,3-b][1,4]OXAZIN-7-YL)-N-(4-Morpholinophenyl)IMIDAZO[1,2-a]PYRAZIN-8-Amine AS A SPLEEN TYROSINE KINASE INHIBITOR
In force
 · High confidence
In forceHigh confidence
US 9,796,7186-(BENZO[d]THIAZOL-5-YL)-N-(3,4-Dimethoxyphenyl)IMIDAZO[1,2-a]PYRAZIN-8-Amine
In force
 · High confidence
In forceHigh confidence
US 9,382,256Formulation of Syk inhibitors
In force
 · USPTO record
In forceUSPTO record
US 9,657,023Polymorph of Syk inhibitors
In force
 · USPTO record
In forceUSPTO record
US 9,918,939Formulation of Syk inhibitors
In force
 · USPTO record
In forceUSPTO record
US 10,266,539Polymorph of Syk inhibitors
In force
 · USPTO record
In forceUSPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 11 patents in force now held by others · 19 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned · 2 no status recorded

Showing 1 to 4 of 4, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/957,450CRYSTALLINE FORMS OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[l,2-a]PYRAZIN-8-AMINE AS SYK INHIBITORSNov 22, 2024Pending
18/386,964Nov 3, 2023No status recorded
18/712,666Polymorphic and Salt Forms of (1S,3S)-N1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl) CYCLOPENTANE-1,3-DiamineNov 22, 2022Abandoned
18/034,634Nov 4, 2021No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited